(WAFB) - Updates issued by the U.S. Food and Drug Administration (FDA) Wednesday, Oct. 23 show more products used to relieve and prevent heartburn are being recalled due to the potential presence of the same probable cancer-causing impurity that prompted a July recall of several blood pressure medications.
The FDA first learned Friday, Sept. 13 that some medicines containing Ranitidine were possibly contaminated with small amounts of a substance called N-nitrosodimethylamine, or NDMA.
On Wednesday, Sept. 25, Apotex Corp. a manufacturer of heartburn medications that include Ranitidine, formally announced a nationwide recall on its products. The impacted products include 75mg and 150mg tablets. All pack sizes and formats were recalled.
The affected Ranitidine Hydrochloride Tablets can be identified by NDC numbers stated on the product label which are identified below:
Executives at CVS would later announce on Monday, Saturday. 28 that a decision was made to stop selling the company’s own generic version heartburn medication that contains Ranitidine, and Zantac.
On Tuesday, Oct. 1 Dr. Reddy’s Laboratories along with its subsidiaries initiated a recall on all of its Ranitidine medications sold in U.S.
Dr. Reddy’s Ranitidine products can be identified by NDC numbers on the product label. All Ranitidine products with expiration dated September 2019 to June 2021 are being recalled. These products were sold at popular retailers such as Walmart, CVS, Kroger, Target, and Walgreens. The full list can be viewed by clicking the link here.
Drugmaker Sanofi, the manufacturer of Zantac, later initiated a recall in the U.S. and Canada on Friday, Oct. 18 because of possible contamination.
On Friday, October 25 Novitium Pharma voluntarily recalled all quantities and lots of its Ranitidine Hydrochloride Capsules listed in the link here.
The FDA previously said those on a prescription version of medications that include ranitidine who want to discontinue use should talk to their doctor about other treatment options.